StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research report report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Shares of Aeterna Zentaris stock opened at $1.98 on Monday. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.38. The stock’s fifty day moving average is $1.98 and its 200 day moving average is $1.89. The stock has a market cap of $9.62 million, a P/E ratio of -0.58 and a beta of 1.57.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last posted its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.19). The business had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Featured Stories
- Five stocks we like better than Aeterna Zentaris
- Golden Cross Stocks: Pattern, Examples and Charts
- High-Yield Texas Instruments Could Hit New Highs Soon
- What Are the U.K. Market Holidays? How to Invest and Trade
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Breakout Stocks: What They Are and How to Identify Them
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.